Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.

Novo Nordisk is likely to draw investor attention on Monday after the company said it is moving forward with the oral and subcutaneous forms of its investigational obesity drug amycretin following early clinical studies showing up to 24.

Novo Nordisk on Friday said full results from early-stage trials show that its experimental drug, amycretin, helped overweight and obese adults lose up to 24% of their weight as the Danish company readies for late-stage studies to start next year.